BRADY MOFFETT to Obesity
This is a "connection" page, showing publications BRADY MOFFETT has written about Obesity.
Connection Strength
1.417
-
The "Ideal" Body Weight for Pediatric Gentamicin Dosing in the Era of Obesity: A Population Pharmacokinetic Analysis. Ther Drug Monit. 2018 06; 40(3):322-329.
Score: 0.272
-
Assessment of inpatient admissions and top 25 medications for obese pediatric patients at two academic hospitals. Am J Health Syst Pharm. 2016 Aug 15; 73(16):1243-9.
Score: 0.238
-
Impact of Body Habitus on Phenytoin Levels Following Fosphenytoin Loading Dose in Pediatric Patients. Ther Drug Monit. 2015 Dec; 37(6):772-5.
Score: 0.229
-
Response to warfarin therapy in obese pediatric patients dosed according to institutional guidelines. J Pediatr Hematol Oncol. 2014 Nov; 36(8):e487-9.
Score: 0.212
-
Heparin dosing in obese pediatric patients in the cardiac catheterization laboratory. Ann Pharmacother. 2011 Jul; 45(7-8):876-80.
Score: 0.169
-
Vancomycin dosing in obese pediatric patients. Clin Pediatr (Phila). 2011 May; 50(5):442-6.
Score: 0.164
-
Evaluation of weight-based dosing of unfractionated heparin in obese children. J Pediatr. 2013 Jul; 163(1):150-3.
Score: 0.047
-
Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin. J Pediatr. 2013 Feb; 162(2):293-6.
Score: 0.046
-
Altered gentamicin serum concentrations in obese pediatric patients. Pediatr Infect Dis J. 2011 Apr; 30(4):347-9.
Score: 0.041